G. Edward Griffin - Author of scientific report that identifies new "superbug" says he was hired by the EU and two pharmaceutical companies who then twisted his work to create a demand for products produced by the companies and to frighten people away from leaving Europe to seek medical treatment in India.
The Times of India
CHENNAI: A day after the Lancet report on a drug-resistant superbug NDM-1 created a global scare, India hit out at the study, which it said was funded by pharma companies that make antibiotics to treat such cases. While the Union health ministry issued a statement on Thursday, which took offence to the naming of the bug after the national capital, the report's Chennai-based lead authorKarthikeyan Kumarasamy dissociated himself from parts of it.
"The study was funded by the European Union and two pharmaceutical companies, Wellcome Trust and Wyeth, which produce antibiotics for treatment of such cases. It also needs to be highlighted that several of the authors have declared conflict of interest in the publication," the health ministry said.
Kumarasamy said he had not written many of the interpretations in the report; they were added later without his permission or knowledge. "I do not agree with the last paragraph which advises people to avoid elective surgeries in India. While I did the scientific work, correspondence author Timothy R Walsh of Cardiff University was assigned to edit the report," he told TOI. According to the study, based on a survey of patients in Indian cities, a multi-drug resistant strain of bacteria was spreading from Indian hospitals.
No comments:
Post a Comment